Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

56 evidence topics · 30 sources

Heterogeneity of treatment effect

No evidence found.

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.